Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michaela Fontenay

Dyserythropoiesis Evaluated by RED Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes

Haematologica

Hematology

2018

English

CD13 Expression in B Cell Malignancies Is a Hallmark of Plasmacytic Differentiation

British Journal of Haematology

Hematology

2018

English

Related publications

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology

English

Correction To: The Prognostic Value of Serum Erythropoietin in Patients With Lower-Risk Myelodysplastic Syndromes: A Review of the Literature and Expert Opinion

English

High Serum Erythropoietin and Ferritin Levels Associated With Anemia Response in Malignant Lymphoma

Mediterranean Journal of Hematology and Infectious Diseases

Infectious Diseases

Hematology

2011

English

Flow Cytometric Detection of Dyserythropoiesis: A Sensitive and Powerful Diagnostic Tool for Myelodysplastic Syndromes

English

Mutations and Karyotype Predict Treatment Response in Myelodysplastic Syndromes

American Journal of Hematology

Hematology

2018

English

Treatment of Anemia in Low Risk Myelodysplastic Syndromes With Granulocyte–macrophage Colony-Stimulating Factor Plus Recombinant Human Erythropoietin

English

Long-Term Outcome of Immunosuppressive Therapy for Japanese Patients With Lower-Risk Myelodysplastic Syndromes

International Journal of Hematology

Hematology

2013

English

Polymorphism of the Erythropoietin Gene Promotor and the Development of Myelodysplastic Syndromes Subsequent to Multiple Myeloma

English

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michaela Fontenay

Dyserythropoiesis Evaluated by RED Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes

CD13 Expression in B Cell Malignancies Is a Hallmark of Plasmacytic Differentiation

Related publications

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Correction To: The Prognostic Value of Serum Erythropoietin in Patients With Lower-Risk Myelodysplastic Syndromes: A Review of the Literature and Expert Opinion

High Serum Erythropoietin and Ferritin Levels Associated With Anemia Response in Malignant Lymphoma

Flow Cytometric Detection of Dyserythropoiesis: A Sensitive and Powerful Diagnostic Tool for Myelodysplastic Syndromes

Mutations and Karyotype Predict Treatment Response in Myelodysplastic Syndromes

Treatment of Anemia in Low Risk Myelodysplastic Syndromes With Granulocyte–macrophage Colony-Stimulating Factor Plus Recombinant Human Erythropoietin

Long-Term Outcome of Immunosuppressive Therapy for Japanese Patients With Lower-Risk Myelodysplastic Syndromes

Polymorphism of the Erythropoietin Gene Promotor and the Development of Myelodysplastic Syndromes Subsequent to Multiple Myeloma

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes